- Home
- STIM
STIM
Neuronetics Inc.
as 12-20-2024 4:00pm EST
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 36.1M | IPO Year: | 2018 |
| Target Price: | $4.67 | AVG Volume (30 days): | 255.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $5.07 | Next Earning Date: | 11-12-2024 |
| Revenue: | $72,711,000 | Revenue Growth: | 5.03% |
| Revenue Growth (this year): | 1.97% | Revenue Growth (next year): | 7.96% |
Stock Insider Trading Activity of Neuronetics Inc. (STIM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MACAN WILLIAM ANDREW | STIM | EVP, GC, CCO and CS | Oct 8 '24 | Sell | $0.82 | 1,541 | $1,263.62 | 402,792 | |
| Furlong Stephen | STIM | EVP, CFO and Treasurer | Oct 8 '24 | Sell | $0.82 | 1,368 | $1,121.76 | 497,408 |
Latest Neuronetics Inc. News
STIM Breaking Stock News: Dive into STIM Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5 days ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
11 days ago
Neuronetics and Greenbrook TMS Announce Closing of Transaction
GlobeNewswire
a month ago
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Simply Wall St.
a month ago
Neuronetics Third Quarter 2024 Earnings: Misses Expectations
Simply Wall St.
a month ago
Need To Know: The Consensus Just Cut Its Neuronetics, Inc. (NASDAQ:STIM) Estimates For 2025
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/15/2024
Simply Wall St.
a month ago
Neuronetics, Inc. (NASDAQ:STIM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Compare STIM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STIM Neuronetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.